Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pediatric PAH patients | US pediatric population with PAH in MarketScan database during the period 2010-2013 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Assigned pulmonary hypertension medication | Drug | As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence rate of PAH (pulmonary arterial hypertension) | Retrospective analysis of three year period | |
| Prevalence rate of PAH | Retrospective analysis of three year period |
| Measure | Description | Time Frame |
|---|---|---|
| Assigned drug treatment for PAH measured using the MarketScan database | Description of pulmonary hypertension-targeted drugs prescribed in the study population and changes during the study period | Retrospective analysis of three year period |
| Diagnostic procedures performed among PAH patients measured using the MarketScan database |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not applicable
Not provided
Not provided
Not provided
The study population will be all patients who were born after 1991 and thus under the age of 18 during the years 2010 to 2013 in the MarketScan data. The larger population of patients under age 18 will comprise the general population from which population-based prevalence rates will be derived.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boston | Massachusetts | United States |
Not provided
| ID | Term |
|---|---|
| D006976 | Hypertension, Pulmonary |
| D000081029 | Pulmonary Arterial Hypertension |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Retrospective analysis of three year period |
| Prevalence of comorbidities among PAH patients | Retrospective analysis of three year period |
| D002318 |
| Cardiovascular Diseases |